U.S. Markets open in 49 mins

Wired News - Microbot Medical Shares Results from the In-Vitro Study of its Self-Cleaning Shunt

Stock Monitor: Bovie MedicalPost Earnings Reporting

LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company's latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company's Self-Cleaning Shunt (SCS). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=BVX

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Microbot Medical most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=MBOT

About the Self-Cleaning Shunt

The Microbot SCS is a robotic system, specifically designed as the ventricular catheter portion of a Cerebrospinal Fluid (CSF) shunt system. Microbot's ventricular catheter is able to connect to existing valves and maintain CSF flow through the ventricular catheter. This SCS device has the potential to replace all ventricular catheters, and also significantly reduce shunts occlusions. At present, there is a 40% rate of occlusions within the first year of implementation.

Encouraging Results from the In-Vitro Study

Dr. Carolyn Harris, Assistant Professor of Chemical Engineering and Materials Science at Wayne State University conducted the study in an in-vitro 3D cell culture system, in order to replicate the ventricular environment. The study, which was conducted at the Wayne State University, validates SCS's potential as a feasible technology for preventing occlusion in shunts used to treat hydrocephalus.

Dr. Harris shared that the initial results from the study demonstrate that cells attach, grow, and spread across the shunt drainage holes of the Microbot SCS. This study shows that Microbot SCS has the potential to remove the early spreading of cells across the shunt holes, which is a first step towards the main target of the study, i.e. occlusion prevention. However, further research is required to confirm this.

Harel Gadot, Chief Executive Officer, President, and Chairman at Microbot Medical, stated that these encouraging results affirm the Company's confidence in the SCS' technology, which is a novel solution to avert occlusion in hydrocephalus shunts, and also a potential platform for future occlusion prevention devices for other medical applications. The Company has been executing the next development phase of its SCS and has recently upgraded its facility to support these activities.

According to Gadot, with these improvements, Microbot expects to deliver the first occlusion prevention device for the numerous patients suffering from hydrocephalus while eliminating redundant procedures and reducing the cost of healthcare.

A US Patent for SCS

On May 09, 2018, Microbot announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Patent Application No. 15/187,003, for the Company's SCS device. This application is a continuation of Patent No. 9,393,389, which was issued on July 19, 2016.

Way Ahead for SCS

Microbot intends to initiate larger-scale studies to support the SCS and prepare it for regulatory submissions in the USA, Europe, and other regions of the world.

Stock Performance Snapshot

May 22, 2018 - At Tuesday's closing bell, Microbot Medical's stock dropped 4.62%, ending the trading session at $0.91.

Volume traded for the day: 2.19 million shares, which was above the 3-month average volume of 309.11 thousand shares.

Stock performance in the last month – up 14.65%; and previous three-month period – up 13.97%

After yesterday's close, Microbot Medical's market cap was at $38.00 million.

The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

  • Bank of America Has Seen the Future: A U.S. Stock Roller Coaster
    Business
    Bloomberg

    Bank of America Has Seen the Future: A U.S. Stock Roller Coaster

    Bank of America Merrill Lynch’s equity and quant team say market signals from the ever-flattening yield curve are clear as day: stock markets are due to begin a new era of elevated price swings. “A flattening yield curve signaled a withdrawal of liquidity and over the last three cycles has preceded rising volatility by a few years,” the team, including Savita Subramanian, wrote in research this week. Bank of America’s call -- echoing others -- comes as investors scramble to judge whether the current turmoil in equity markets represents a blip or fundamental shift in regime.

  • One of the largest cannabis companies is going public on the New York Stock Exchange
    Business
    Business Insider

    One of the largest cannabis companies is going public on the New York Stock Exchange

    Aurora Cannabis, one of the largest Canadian marijuana producers, is going public on the New York Stock Exchange. Aurora is joining a select list of Canadian cannabis producers, including Tilray and Cronos, that are able to list on US-based exchanges.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • China Will Open the World's Longest Sea Bridge This Week. A Lot of People Are Unhappy About It
    World
    Fortune

    China Will Open the World's Longest Sea Bridge This Week. A Lot of People Are Unhappy About It

    Later this week, the long-awaited 34-mile sea bridge connecting mainland China to Hong Kong and Macau will finally open. In a ceremony on Tuesday that Chinese president Xi Jinping will reportedly attend, the bridge will officially open. Some critics see the Hong Kong-Zhuhai-Macau Bridge as an attempt by mainland China to tighten its grip on Hong Kong, which is an autonomous region.

  • Finance
    CNBC

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson
    News
    MarketWatch

    Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson

    October is living up to its infamous reputation as a volatile month for stocks with major indexes down sharply and there is likely more pain ahead for investors, according to one prominent Wall Street analyst. The recent rebound “was a dead cat bounce,” said Michael Wilson, an equity strategist at Morgan Stanley, in a report. After eking out gains last week, the S&P 500 (SPX) is trading below the 200 DMA of 2,768 Monday as stocks struggle for direction with third-quarter earnings cycle picking up pace.

  • 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade
    Business
    Motley Fool

    5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

    October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

  • Trump Floats 10% Middle Class Tax Cut With Election Looming. The Only Problem: Congress Isn’t in Session
    Business
    Fortune

    Trump Floats 10% Middle Class Tax Cut With Election Looming. The Only Problem: Congress Isn’t in Session

    President Donald Trump announced a new 10% tax cut would come into effect before the midterms, intended only for the middle class, not for businesses—nor the rich. Congress isn’t in session, congressional leaders haven’t heard about it, nothing has been drafted, and Trump seemed to have invented it from whole cloth on Oct. 20, based on a confirmation provided by a White House spokesperson who spoke to CNBC. Trump’s talk of a 10% tax cut comes a few weeks after the House took advantage of the attention focused on the Senate confirmation hearings for Supreme Court justice Brett Kavanaugh to pass $3.8 trillion in additional tax cuts on top of the December 2017 changes.

  • These stocks may be sacrificed in a cold war with China
    COL
    CNBC Videos

    These stocks may be sacrificed in a cold war with China

    Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

  • Business
    Benzinga

    Corning Q3 Earnings Preview

    Corning Incorporated (NYSE: GLW) announces its next round of earnings this Tuesday, Oct. 23. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement. Earnings and Revenue Based on management's projections, Corning analysts model

  • Why Is Yamana Gold on Many Analysts’ Wish Lists?
    Finance
    Market Realist

    Why Is Yamana Gold on Many Analysts’ Wish Lists?

    Analysts’ Views: Is It Time to Look at Gold Miners? According to the consensus compiled by Thomson Reuters, 71% of analysts covering Yamana Gold (AUY) stock have recommended a “buy,” while 15% have recommended a “hold.” AUY’s target price represents an upside potential of 54% based on its current market price. Yamana’s “buy” ratings have improved to the current level of 71% from nearly 31% a year ago.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • Shares of downtrodden IBM 'ready to roar higher': Charts
    Business
    CNBC Videos

    Shares of downtrodden IBM 'ready to roar higher': Charts

    Jim Cramer and technician Larry Williams inspect the charts of IBM, which seem to show the beleaguered tech stock on the cusp of a rally.

  • A North Carolina Police Officer Fatally Shot a Black Motorist During a Traffic Stop
    News
    Time

    A North Carolina Police Officer Fatally Shot a Black Motorist During a Traffic Stop

    The shooting happened Sunday afternoon, Stacy Drakeford, director of Washington police and fire services, said in a statement. Drakeford said after the car was stopped, the driver got out of his vehicle with a gun. The officer then shot the man, who was identified as Cedric Pritchard of Washington.

  • Meet What Could Be Advanced Micro Devices' Next Billion-Dollar Business
    Business
    Motley Fool

    Meet What Could Be Advanced Micro Devices' Next Billion-Dollar Business

    Advanced Micro Devices (NASDAQ: AMD) CEO Lisa Su said earlier this year that the company plans to achieve "mid-single-digit server unit share" by the end of 2018. The chipmaker's server chip market share crossed 1% at the end of the second quarter. Mercury Research estimates that AMD now commands 1.3% of the server market as compared to just 0.5% earlier.

  • 4 Things Aurora Cannabis Did Right Before Its NYSE Debut
    Business
    Motley Fool

    4 Things Aurora Cannabis Did Right Before Its NYSE Debut

    Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) has sought to make it even easier for U.S. investors to buy its shares by arranging to have its shares listed on the New York Stock Exchange. Beginning tomorrow, Oct. 23, Aurora will join the elite group of cannabis companies whose shares trade on major U.S. exchanges. Getting ready for the increased exposure that a NYSE listing brings takes time and effort, and Aurora Cannabis hasn't wasted any time.

  • Business
    Bloomberg

    Shell's Up Next, And Last, in $200 Billion Australia LNG Bonanza

    Australia’s nine-year, $200 billion boom in liquefied natural gas still has a final debut in the works: Royal Dutch Shell Plc’s Prelude, floating 200 kilometers (124 miles) off its northwest coast. It’s the last project in that investment cycle to start production after Japan’s Inpex Corp. shipped its maiden cargo from Ichthys LNG on Monday. Shell’s Prelude is among seven export projects in gas-rich Australia sanctioned since 2009 by global energy giants including Chevron Corp. and Exxon Mobil Corp., as well as regional big hitters such as Australia’s Woodside Petroleum Ltd. and Malaysia’s Petroleum Nasional Bhd. The Pacific nation now rivals Qatar as the world’s biggest seller of LNG, a form of natural gas super-chilled into a liquid that can be shipped on tankers.

  • Is the New Energy Transfer LP a Buy?
    Finance
    Motley Fool

    Is the New Energy Transfer LP a Buy?

    Last week, Energy Transfer LP (NYSE: ET) emerged on the scene after the former Energy Transfer Equity completed the acquisition of its affiliate Energy Transfer Partners in a unit-for-unit exchange that simplified this complex midstream franchise. The transaction also created a much stronger company that has the financial resources to fund a significant slate of expansion projects. The new Energy Transfer is a behemoth in the midstream sector.

  • Cannabis Stocks Aren't Just Plunging, They've Already Fallen Into Bear Market Territory
    Business
    Fortune

    Cannabis Stocks Aren't Just Plunging, They've Already Fallen Into Bear Market Territory

    Maybe it’s just a sign that autumn is here, but marijuana stocks like Tilray and Aurora Cannabis have suddenly turned from green to red. Key stocks in the budding cannabis sector have lost more than 20% in the past week—a figure that is typically used to measure a bear market. Meanwhile, the Horizons Marijuana Life Sciences ETF, which is traded on the Toronto Stock Exchange, fell 11.6% Monday and 24.3% in the past week.

  • Why Pot Stocks Canopy Growth, Cronos Group, and Tilray Are Cratering Today
    Business
    Motley Fool

    Why Pot Stocks Canopy Growth, Cronos Group, and Tilray Are Cratering Today

    Canadian pot stocks are getting hit hard across the board today. As of 1:21 p.m. EDT, for example, shares of Canopy Growth Corporation (NYSE: CGC) and Cronos Group (NASDAQ: CRON) were both down by 11.2%, whereas Tilray's(NASDAQ: TLRY) stock had fallen by 14.4%. Canopy, Cronos, and Tilray all seem to be succumbing to a so-called "sell the news" event.

  • 3 Things to Watch When ConocoPhillips Reports Q3 Results
    Business
    Motley Fool

    3 Things to Watch When ConocoPhillips Reports Q3 Results

    ConocoPhillips (NYSE: COP) is having an impressive year. The company could potentially add even more fuel to continue rallying later this week when it announces its third-quarter results. In the second quarter, ConocoPhillips produced an average of 1.211 million barrels of oil equivalent per day (BOE/D), which was just above the top end of its guidance range and 5% higher than the year-ago period after adjusting for asset sales.

  • SC senator says state law on nuclear construction to be ruled unconstitutional, putting Dominion-SCANA deal at risk
    Finance
    American City Business Journals

    SC senator says state law on nuclear construction to be ruled unconstitutional, putting Dominion-SCANA deal at risk

    A South Carolina circuit judge intends to declare the S.C. Base Load Review Act unconstitutional and has asked lawyers in the cases challenging the law to prepare proposed orders before his final ruling, a state senator says. The expected ruling could force S.C. Electric & Gas to repay customers hundreds of millions of dollars it has already collected to pay its $5 billion share of almost $9 billion spent on the now-abandoned V.C. Summer nuclear plant expansion. It would likely prevent the utility from recovering those costs in the future and could jeopardize Dominion Energy Inc.’s proposed $14.6 billion deal to buy the utility’s parent SCANA Corp, based in Cayce, S.C. S.C. Sen. Brad Hutto said Friday the formal ruling is expected in weeks.

  • 2 Things to Watch When Ford Motor Company Reports Earnings
    Business
    Motley Fool

    2 Things to Watch When Ford Motor Company Reports Earnings

    Wall Street analysts expect Ford's earnings to fall from the third quarter of 2017. Ford has refreshed the Explorer twice since its 2011 debut, but its age is hurting Ford's pricing power. 1. How soon will Ford's new products arrive?

  • Aurora Cannabis prepares for NYSE debut on Oct. 23
    Finance
    Yahoo Finance Canada

    Aurora Cannabis prepares for NYSE debut on Oct. 23

    One of Canada’s largest marijuana producers is gearing up for its big debut on the New York Stock Exchange on Tuesday, Oct. 23. Edmonton-based Aurora Cannabis will be the third major Canadian cannabis company to go public in the U.S., where marijuana is still an illegal substance in most states. Aurora will be following in the steps of Tilray, which became the first U.S. marijuana IPO in July, and Canopy Growth, which debuted in the U.S. markets in May.